JP2007509118A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007509118A5 JP2007509118A5 JP2006536171A JP2006536171A JP2007509118A5 JP 2007509118 A5 JP2007509118 A5 JP 2007509118A5 JP 2006536171 A JP2006536171 A JP 2006536171A JP 2006536171 A JP2006536171 A JP 2006536171A JP 2007509118 A5 JP2007509118 A5 JP 2007509118A5
- Authority
- JP
- Japan
- Prior art keywords
- cyclopropyl
- alkyl
- oxoquinazolin
- methyl
- methylbenzamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 412
- -1 hydroxy, amino Chemical group 0.000 claims description 248
- 125000003545 alkoxy group Chemical group 0.000 claims description 166
- 125000001424 substituent group Chemical group 0.000 claims description 120
- 125000000623 heterocyclic group Chemical group 0.000 claims description 68
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 64
- 125000003282 alkyl amino group Chemical group 0.000 claims description 60
- 125000005843 halogen group Chemical group 0.000 claims description 51
- 150000001875 compounds Chemical class 0.000 claims description 45
- 125000003342 alkenyl group Chemical group 0.000 claims description 44
- 125000000304 alkynyl group Chemical group 0.000 claims description 44
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 40
- 229910052757 nitrogen Inorganic materials 0.000 claims description 37
- 150000003839 salts Chemical class 0.000 claims description 34
- 125000004432 carbon atom Chemical group C* 0.000 claims description 31
- 229910052799 carbon Inorganic materials 0.000 claims description 29
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 26
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 26
- 125000001072 heteroaryl group Chemical group 0.000 claims description 26
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 26
- 125000001589 carboacyl group Chemical group 0.000 claims description 25
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 24
- 125000005115 alkyl carbamoyl group Chemical group 0.000 claims description 22
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 17
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 15
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 15
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 15
- 125000004043 oxo group Chemical group O=* 0.000 claims description 15
- 125000001153 fluoro group Chemical group F* 0.000 claims description 14
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 13
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 13
- 229910052739 hydrogen Inorganic materials 0.000 claims description 13
- 239000001257 hydrogen Substances 0.000 claims description 13
- 150000001721 carbon Chemical group 0.000 claims description 12
- JQCSUVJDBHJKNG-UHFFFAOYSA-N 1-methoxy-ethyl Chemical group C[CH]OC JQCSUVJDBHJKNG-UHFFFAOYSA-N 0.000 claims description 10
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims description 10
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 claims description 10
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 9
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 9
- 125000004414 alkyl thio group Chemical group 0.000 claims description 9
- 125000003118 aryl group Chemical group 0.000 claims description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 8
- 125000000524 functional group Chemical group 0.000 claims description 8
- 108090000695 Cytokines Proteins 0.000 claims description 7
- 102000004127 Cytokines Human genes 0.000 claims description 7
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 7
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims description 6
- 125000006239 protecting group Chemical group 0.000 claims description 6
- 125000005999 2-bromoethyl group Chemical group 0.000 claims description 5
- 125000001340 2-chloroethyl group Chemical group [H]C([H])(Cl)C([H])([H])* 0.000 claims description 5
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 claims description 5
- 125000003006 2-dimethylaminoethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims description 5
- 125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 claims description 5
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims description 5
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 claims description 5
- 125000005997 bromomethyl group Chemical group 0.000 claims description 5
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 claims description 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 5
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 claims description 5
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 5
- 125000004772 dichloromethyl group Chemical group [H]C(Cl)(Cl)* 0.000 claims description 5
- 125000006264 diethylaminomethyl group Chemical group [H]C([H])([H])C([H])([H])N(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 claims description 5
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 125000006125 ethylsulfonyl group Chemical group 0.000 claims description 5
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims description 5
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 5
- 125000004742 propyloxycarbonyl group Chemical group 0.000 claims description 5
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 5
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 5
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 4
- 125000005241 heteroarylamino group Chemical group 0.000 claims description 4
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 4
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 claims description 3
- FDPVTENMNDHFNK-UHFFFAOYSA-N 2-amino-n-phenylbenzamide Chemical compound NC1=CC=CC=C1C(=O)NC1=CC=CC=C1 FDPVTENMNDHFNK-UHFFFAOYSA-N 0.000 claims description 3
- 208000030507 AIDS Diseases 0.000 claims description 3
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 3
- 206010019280 Heart failures Diseases 0.000 claims description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 3
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- 206010040070 Septic Shock Diseases 0.000 claims description 3
- 238000010976 amide bond formation reaction Methods 0.000 claims description 3
- 208000006673 asthma Diseases 0.000 claims description 3
- 150000002431 hydrogen Chemical class 0.000 claims description 3
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 208000031225 myocardial ischemia Diseases 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 230000036303 septic shock Effects 0.000 claims description 3
- 238000002560 therapeutic procedure Methods 0.000 claims description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 2
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 2
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 2
- HCPMOUXUWOUFKH-UHFFFAOYSA-N n-cyclobutyl-4-methyl-3-[6-(4-methylpiperazin-1-yl)-4-oxoquinazolin-3-yl]benzamide Chemical group C1CN(C)CCN1C1=CC=C(N=CN(C=2C(=CC=C(C=2)C(=O)NC2CCC2)C)C2=O)C2=C1 HCPMOUXUWOUFKH-UHFFFAOYSA-N 0.000 claims description 2
- XHFABWPTYFWNFH-UHFFFAOYSA-N n-cyclopropyl-3-[6-(1,4-diazepan-1-yl)-4-oxoquinazolin-3-yl]-4-methylbenzamide Chemical group CC1=CC=C(C(=O)NC2CC2)C=C1N(C(C1=C2)=O)C=NC1=CC=C2N1CCCNCC1 XHFABWPTYFWNFH-UHFFFAOYSA-N 0.000 claims description 2
- HUDRXSXKLYHUBS-UHFFFAOYSA-N n-cyclopropyl-3-[6-[1-(cyclopropylmethyl)piperidin-4-yl]oxy-4-oxoquinazolin-3-yl]-4-methylbenzamide Chemical group CC1=CC=C(C(=O)NC2CC2)C=C1N(C(C1=C2)=O)C=NC1=CC=C2OC(CC1)CCN1CC1CC1 HUDRXSXKLYHUBS-UHFFFAOYSA-N 0.000 claims description 2
- JZLORZUOLUEHEM-UHFFFAOYSA-N n-cyclopropyl-4-methyl-3-(4-oxo-6-piperazin-1-ylquinazolin-3-yl)benzamide Chemical group CC1=CC=C(C(=O)NC2CC2)C=C1N(C(C1=C2)=O)C=NC1=CC=C2N1CCNCC1 JZLORZUOLUEHEM-UHFFFAOYSA-N 0.000 claims description 2
- MATLJYUMZLLGDA-UHFFFAOYSA-N n-cyclopropyl-4-methyl-3-(4-oxo-6-piperidin-4-yloxyquinazolin-3-yl)benzamide Chemical group CC1=CC=C(C(=O)NC2CC2)C=C1N(C(C1=C2)=O)C=NC1=CC=C2OC1CCNCC1 MATLJYUMZLLGDA-UHFFFAOYSA-N 0.000 claims description 2
- QCRGVBHYRARZNG-UHFFFAOYSA-N n-cyclopropyl-4-methyl-3-[4-oxo-6-(4-propan-2-ylpiperazin-1-yl)quinazolin-3-yl]benzamide Chemical compound C1CN(C(C)C)CCN1C1=CC=C(N=CN(C=2C(=CC=C(C=2)C(=O)NC2CC2)C)C2=O)C2=C1 QCRGVBHYRARZNG-UHFFFAOYSA-N 0.000 claims description 2
- SSBANYVKJLMCBN-UHFFFAOYSA-N n-cyclopropyl-4-methyl-3-[4-oxo-6-(4-propylpiperazin-1-yl)quinazolin-3-yl]benzamide Chemical compound C1CN(CCC)CCN1C1=CC=C(N=CN(C=2C(=CC=C(C=2)C(=O)NC2CC2)C)C2=O)C2=C1 SSBANYVKJLMCBN-UHFFFAOYSA-N 0.000 claims description 2
- ZMAZXHICVRYLQN-UHFFFAOYSA-N n-cyclopropyl-4-methyl-3-[6-(4-methylpiperazin-1-yl)-4-oxoquinazolin-3-yl]benzamide Chemical group C1CN(C)CCN1C1=CC=C(N=CN(C=2C(=CC=C(C=2)C(=O)NC2CC2)C)C2=O)C2=C1 ZMAZXHICVRYLQN-UHFFFAOYSA-N 0.000 claims description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 2
- 230000001404 mediated effect Effects 0.000 claims 5
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 4
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 3
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 125000006432 1-methyl cyclopropyl group Chemical group [H]C([H])([H])C1(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000004484 1-methylpiperidin-4-yl group Chemical group CN1CCC(CC1)* 0.000 claims 1
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- DVXQJRHVCWLHHO-UHFFFAOYSA-N 2-[4-[3-[5-(cyclopropylcarbamoyl)-2-methylphenyl]-4-oxoquinazolin-6-yl]piperazin-1-yl]acetic acid Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C(C1=C2)=O)C=NC1=CC=C2N1CCN(CC(O)=O)CC1 DVXQJRHVCWLHHO-UHFFFAOYSA-N 0.000 claims 1
- 125000000979 2-amino-2-oxoethyl group Chemical group [H]C([*])([H])C(=O)N([H])[H] 0.000 claims 1
- WJAJSHFYWOTWBJ-UHFFFAOYSA-N 3-[6-(2-acetamidoethoxy)-4-oxoquinazolin-3-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound O=C1C2=CC(OCCNC(=O)C)=CC=C2N=CN1C(C(=CC=1)C)=CC=1C(=O)NC1CC1 WJAJSHFYWOTWBJ-UHFFFAOYSA-N 0.000 claims 1
- FICYFFIZSUQGHH-UHFFFAOYSA-N 3-[6-(4-acetylpiperazin-1-yl)-4-oxoquinazolin-3-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound C1CN(C(=O)C)CCN1C1=CC=C(N=CN(C=2C(=CC=C(C=2)C(=O)NC2CC2)C)C2=O)C2=C1 FICYFFIZSUQGHH-UHFFFAOYSA-N 0.000 claims 1
- RHDNMCREZVZWHW-UHFFFAOYSA-N 3-[6-(4-cyclobutylpiperazin-1-yl)-4-oxoquinazolin-3-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C(C1=C2)=O)C=NC1=CC=C2N(CC1)CCN1C1CCC1 RHDNMCREZVZWHW-UHFFFAOYSA-N 0.000 claims 1
- UKEPZCHVAWBLRH-UHFFFAOYSA-N 3-[6-[2-(azetidin-1-yl)ethoxy]-4-oxoquinazolin-3-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C(C1=C2)=O)C=NC1=CC=C2OCCN1CCC1 UKEPZCHVAWBLRH-UHFFFAOYSA-N 0.000 claims 1
- UIWWFGOEPSHIBK-UHFFFAOYSA-N 3-[6-[2-(tert-butylamino)ethoxy]-4-oxoquinazolin-3-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound C1=C(N2C(C3=CC(OCCNC(C)(C)C)=CC=C3N=C2)=O)C(C)=CC=C1C(=O)NC1CC1 UIWWFGOEPSHIBK-UHFFFAOYSA-N 0.000 claims 1
- UHRLTJJGLOTWIG-UHFFFAOYSA-N 3-[6-[2-[cyclobutylmethyl(methyl)amino]ethoxy]-4-oxoquinazolin-3-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound C1CCC1CN(C)CCOC(C=C1C2=O)=CC=C1N=CN2C(C(=CC=1)C)=CC=1C(=O)NC1CC1 UHRLTJJGLOTWIG-UHFFFAOYSA-N 0.000 claims 1
- CSQOYWGLIIYRSM-UHFFFAOYSA-N 3-[6-[3-[cyclobutylmethyl(methyl)amino]propoxy]-4-oxoquinazolin-3-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound C1CCC1CN(C)CCCOC(C=C1C2=O)=CC=C1N=CN2C(C(=CC=1)C)=CC=1C(=O)NC1CC1 CSQOYWGLIIYRSM-UHFFFAOYSA-N 0.000 claims 1
- GPRFBOGOKHUAOT-UHFFFAOYSA-N 3-[6-[4-(cyanomethyl)piperazin-1-yl]-4-oxoquinazolin-3-yl]-n-cyclopropyl-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C(C1=C2)=O)C=NC1=CC=C2N1CCN(CC#N)CC1 GPRFBOGOKHUAOT-UHFFFAOYSA-N 0.000 claims 1
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- HLUINUXJZPPVQK-UHFFFAOYSA-N 4-methyl-n-(1-methylcyclopropyl)-3-[4-oxo-6-(2-piperidin-1-ylethoxy)quinazolin-3-yl]benzamide Chemical compound CC1=CC=C(C(=O)NC2(C)CC2)C=C1N(C(C1=C2)=O)C=NC1=CC=C2OCCN1CCCCC1 HLUINUXJZPPVQK-UHFFFAOYSA-N 0.000 claims 1
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 206010010356 Congenital anomaly Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 206010061876 Obstruction Diseases 0.000 claims 1
- BAPJBEWLBFYGME-UHFFFAOYSA-N acrylic acid methyl ester Natural products COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 claims 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 claims 1
- 230000001684 chronic effect Effects 0.000 claims 1
- 230000016396 cytokine production Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 125000004705 ethylthio group Chemical group C(C)S* 0.000 claims 1
- OUDISZOHUHEWBI-UHFFFAOYSA-N n-cyclobutyl-4-methyl-3-[4-oxo-6-(4-propan-2-ylpiperazin-1-yl)quinazolin-3-yl]benzamide Chemical compound C1CN(C(C)C)CCN1C1=CC=C(N=CN(C=2C(=CC=C(C=2)C(=O)NC2CCC2)C)C2=O)C2=C1 OUDISZOHUHEWBI-UHFFFAOYSA-N 0.000 claims 1
- IVHSVYVJVSFWFF-UHFFFAOYSA-N n-cyclopropyl-3-(6-hydroxy-4-oxoquinazolin-3-yl)-4-methylbenzamide Chemical compound C1=C(N2C(C3=CC(O)=CC=C3N=C2)=O)C(C)=CC=C1C(=O)NC1CC1 IVHSVYVJVSFWFF-UHFFFAOYSA-N 0.000 claims 1
- CSCSGDAFXRVYLU-UHFFFAOYSA-N n-cyclopropyl-3-(6-iodo-4-oxoquinazolin-3-yl)-4-methylbenzamide Chemical compound C1=C(N2C(C3=CC(I)=CC=C3N=C2)=O)C(C)=CC=C1C(=O)NC1CC1 CSCSGDAFXRVYLU-UHFFFAOYSA-N 0.000 claims 1
- MIHWXBMNRZJFOR-UHFFFAOYSA-N n-cyclopropyl-3-(6-methoxy-4-oxoquinazolin-3-yl)-4-methylbenzamide Chemical compound O=C1C2=CC(OC)=CC=C2N=CN1C(C(=CC=1)C)=CC=1C(=O)NC1CC1 MIHWXBMNRZJFOR-UHFFFAOYSA-N 0.000 claims 1
- VQWNYJDUIDCODQ-UHFFFAOYSA-N n-cyclopropyl-3-(7-fluoro-4-oxoquinazolin-3-yl)-4-methylbenzamide Chemical compound C1=C(N2C(C3=CC=C(F)C=C3N=C2)=O)C(C)=CC=C1C(=O)NC1CC1 VQWNYJDUIDCODQ-UHFFFAOYSA-N 0.000 claims 1
- IPBMVBGFSVPCKG-UHFFFAOYSA-N n-cyclopropyl-3-(7-methoxy-4-oxoquinazolin-3-yl)-4-methylbenzamide Chemical compound C=1C(OC)=CC=C(C2=O)C=1N=CN2C(C(=CC=1)C)=CC=1C(=O)NC1CC1 IPBMVBGFSVPCKG-UHFFFAOYSA-N 0.000 claims 1
- HSGAOPFYDBVZHU-UHFFFAOYSA-N n-cyclopropyl-3-(8-methoxy-4-oxoquinazolin-3-yl)-4-methylbenzamide Chemical compound COC1=CC=CC(C2=O)=C1N=CN2C(C(=CC=1)C)=CC=1C(=O)NC1CC1 HSGAOPFYDBVZHU-UHFFFAOYSA-N 0.000 claims 1
- YKXCKBZVEVRGNU-UHFFFAOYSA-N n-cyclopropyl-3-[6-(1-cyclopropylpiperidin-4-yl)oxy-4-oxoquinazolin-3-yl]-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C(C1=C2)=O)C=NC1=CC=C2OC(CC1)CCN1C1CC1 YKXCKBZVEVRGNU-UHFFFAOYSA-N 0.000 claims 1
- PBQVNJVCYLEJIP-UHFFFAOYSA-N n-cyclopropyl-3-[6-(1-ethylpyrrolidin-3-yl)oxy-4-oxoquinazolin-3-yl]-4-methylbenzamide Chemical compound C1N(CC)CCC1OC1=CC=C(N=CN(C=2C(=CC=C(C=2)C(=O)NC2CC2)C)C2=O)C2=C1 PBQVNJVCYLEJIP-UHFFFAOYSA-N 0.000 claims 1
- LGUCHTJZQMIJFE-UHFFFAOYSA-N n-cyclopropyl-3-[6-(2,3-dihydroxy-2-methylpropoxy)-4-oxoquinazolin-3-yl]-4-methylbenzamide Chemical compound C1=C(N2C(C3=CC(OCC(C)(O)CO)=CC=C3N=C2)=O)C(C)=CC=C1C(=O)NC1CC1 LGUCHTJZQMIJFE-UHFFFAOYSA-N 0.000 claims 1
- PTBIULMNOAVJQF-UHFFFAOYSA-N n-cyclopropyl-3-[6-(2-hydroxy-2-methyl-3-pyrrolidin-1-ylpropoxy)-4-oxoquinazolin-3-yl]-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C(C1=C2)=O)C=NC1=CC=C2OCC(C)(O)CN1CCCC1 PTBIULMNOAVJQF-UHFFFAOYSA-N 0.000 claims 1
- PFHZOXWQGGWOCC-UHFFFAOYSA-N n-cyclopropyl-3-[6-(2-imidazol-1-ylethoxy)-4-oxoquinazolin-3-yl]-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C(C1=C2)=O)C=NC1=CC=C2OCCN1C=CN=C1 PFHZOXWQGGWOCC-UHFFFAOYSA-N 0.000 claims 1
- PFBMSZRTCQZXIN-UHFFFAOYSA-N n-cyclopropyl-3-[6-(3-hydroxyazetidin-1-yl)-4-oxoquinazolin-3-yl]-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C(C1=C2)=O)C=NC1=CC=C2N1CC(O)C1 PFBMSZRTCQZXIN-UHFFFAOYSA-N 0.000 claims 1
- XKZDKVJGPJFVRK-UHFFFAOYSA-N n-cyclopropyl-3-[6-(4-ethyl-1,4-diazepan-1-yl)-4-oxoquinazolin-3-yl]-4-methylbenzamide Chemical compound C1CN(CC)CCCN1C1=CC=C(N=CN(C=2C(=CC=C(C=2)C(=O)NC2CC2)C)C2=O)C2=C1 XKZDKVJGPJFVRK-UHFFFAOYSA-N 0.000 claims 1
- HRONGNIWVAVTFC-UHFFFAOYSA-N n-cyclopropyl-3-[6-(4-hydroxypiperidin-1-yl)-4-oxoquinazolin-3-yl]-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C(C1=C2)=O)C=NC1=CC=C2N1CCC(O)CC1 HRONGNIWVAVTFC-UHFFFAOYSA-N 0.000 claims 1
- LXWSPBJSHTYHKN-UHFFFAOYSA-N n-cyclopropyl-3-[6-[(3-hydroxy-2,2-dimethylpropyl)amino]-4-oxoquinazolin-3-yl]-4-methylbenzamide Chemical compound C1=C(N2C(C3=CC(NCC(C)(C)CO)=CC=C3N=C2)=O)C(C)=CC=C1C(=O)NC1CC1 LXWSPBJSHTYHKN-UHFFFAOYSA-N 0.000 claims 1
- PBQVNJVCYLEJIP-HXUWFJFHSA-N n-cyclopropyl-3-[6-[(3r)-1-ethylpyrrolidin-3-yl]oxy-4-oxoquinazolin-3-yl]-4-methylbenzamide Chemical compound C1N(CC)CC[C@H]1OC1=CC=C(N=CN(C=2C(=CC=C(C=2)C(=O)NC2CC2)C)C2=O)C2=C1 PBQVNJVCYLEJIP-HXUWFJFHSA-N 0.000 claims 1
- GSJAQNVOUNAGFD-LJQANCHMSA-N n-cyclopropyl-3-[6-[(3r)-4-(cyclopropylmethyl)-3-methylpiperazin-1-yl]-4-oxoquinazolin-3-yl]-4-methylbenzamide Chemical compound C([C@H]1C)N(C=2C=C3C(=O)N(C=4C(=CC=C(C=4)C(=O)NC4CC4)C)C=NC3=CC=2)CCN1CC1CC1 GSJAQNVOUNAGFD-LJQANCHMSA-N 0.000 claims 1
- IGYUYYXMKCXLLQ-GOSISDBHSA-N n-cyclopropyl-3-[6-[(3r)-4-ethyl-3-methylpiperazin-1-yl]-4-oxoquinazolin-3-yl]-4-methylbenzamide Chemical compound C1[C@@H](C)N(CC)CCN1C1=CC=C(N=CN(C=2C(=CC=C(C=2)C(=O)NC2CC2)C)C2=O)C2=C1 IGYUYYXMKCXLLQ-GOSISDBHSA-N 0.000 claims 1
- NYDZOAQNQUWWAU-CALCHBBNSA-N n-cyclopropyl-3-[6-[(3r,5s)-3,5-dimethylpiperazin-1-yl]-4-oxoquinazolin-3-yl]-4-methylbenzamide Chemical compound C1[C@@H](C)N[C@@H](C)CN1C1=CC=C(N=CN(C=2C(=CC=C(C=2)C(=O)NC2CC2)C)C2=O)C2=C1 NYDZOAQNQUWWAU-CALCHBBNSA-N 0.000 claims 1
- PNEXVVGLXCTFKG-QFIPXVFZSA-N n-cyclopropyl-3-[6-[(3s)-1-(cyclopropylmethyl)pyrrolidin-3-yl]oxy-4-oxoquinazolin-3-yl]-4-methylbenzamide Chemical compound C([C@@H](C1)OC2=CC=C3N=CN(C(C3=C2)=O)C2=CC(=CC=C2C)C(=O)NC2CC2)CN1CC1CC1 PNEXVVGLXCTFKG-QFIPXVFZSA-N 0.000 claims 1
- PBQVNJVCYLEJIP-FQEVSTJZSA-N n-cyclopropyl-3-[6-[(3s)-1-ethylpyrrolidin-3-yl]oxy-4-oxoquinazolin-3-yl]-4-methylbenzamide Chemical compound C1N(CC)CC[C@@H]1OC1=CC=C(N=CN(C=2C(=CC=C(C=2)C(=O)NC2CC2)C)C2=O)C2=C1 PBQVNJVCYLEJIP-FQEVSTJZSA-N 0.000 claims 1
- UFECOQXRSYPWRA-CALCHBBNSA-N n-cyclopropyl-3-[6-[(3s,5r)-3,5-dimethylpiperazin-1-yl]-2-methyl-4-oxoquinazolin-3-yl]-4-methylbenzamide Chemical compound C1[C@@H](C)N[C@@H](C)CN1C1=CC=C(N=C(C)N(C=2C(=CC=C(C=2)C(=O)NC2CC2)C)C2=O)C2=C1 UFECOQXRSYPWRA-CALCHBBNSA-N 0.000 claims 1
- NZZMNDSXNLRGBA-UHFFFAOYSA-N n-cyclopropyl-3-[6-[1-(2-fluoroethyl)piperidin-4-yl]oxy-4-oxoquinazolin-3-yl]-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C(C1=C2)=O)C=NC1=CC=C2OC1CCN(CCF)CC1 NZZMNDSXNLRGBA-UHFFFAOYSA-N 0.000 claims 1
- GUUJNSXSHCOSIN-UHFFFAOYSA-N n-cyclopropyl-3-[6-[1-(2-hydroxy-2-methylpropyl)piperidin-4-yl]oxy-4-oxoquinazolin-3-yl]-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C(C1=C2)=O)C=NC1=CC=C2OC1CCN(CC(C)(C)O)CC1 GUUJNSXSHCOSIN-UHFFFAOYSA-N 0.000 claims 1
- MBEYHBZHNWESBD-UHFFFAOYSA-N n-cyclopropyl-3-[6-[1-(2-hydroxyethyl)piperidin-4-yl]oxy-4-oxoquinazolin-3-yl]-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C(C1=C2)=O)C=NC1=CC=C2OC1CCN(CCO)CC1 MBEYHBZHNWESBD-UHFFFAOYSA-N 0.000 claims 1
- MHHJHGCPMKRMEL-UHFFFAOYSA-N n-cyclopropyl-3-[6-[1-(2-methoxyethyl)piperidin-4-yl]oxy-4-oxoquinazolin-3-yl]-4-methylbenzamide Chemical compound C1CN(CCOC)CCC1OC1=CC=C(N=CN(C=2C(=CC=C(C=2)C(=O)NC2CC2)C)C2=O)C2=C1 MHHJHGCPMKRMEL-UHFFFAOYSA-N 0.000 claims 1
- PNEXVVGLXCTFKG-UHFFFAOYSA-N n-cyclopropyl-3-[6-[1-(cyclopropylmethyl)pyrrolidin-3-yl]oxy-4-oxoquinazolin-3-yl]-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C(C1=C2)=O)C=NC1=CC=C2OC(C1)CCN1CC1CC1 PNEXVVGLXCTFKG-UHFFFAOYSA-N 0.000 claims 1
- LNAVQPIOKWMYGV-GOSISDBHSA-N n-cyclopropyl-3-[6-[1-[(2r)-2-hydroxypropyl]piperidin-4-yl]oxy-4-oxoquinazolin-3-yl]-4-methylbenzamide Chemical compound C1CN(C[C@H](O)C)CCC1OC1=CC=C(N=CN(C=2C(=CC=C(C=2)C(=O)NC2CC2)C)C2=O)C2=C1 LNAVQPIOKWMYGV-GOSISDBHSA-N 0.000 claims 1
- LNAVQPIOKWMYGV-SFHVURJKSA-N n-cyclopropyl-3-[6-[1-[(2s)-2-hydroxypropyl]piperidin-4-yl]oxy-4-oxoquinazolin-3-yl]-4-methylbenzamide Chemical compound C1CN(C[C@@H](O)C)CCC1OC1=CC=C(N=CN(C=2C(=CC=C(C=2)C(=O)NC2CC2)C)C2=O)C2=C1 LNAVQPIOKWMYGV-SFHVURJKSA-N 0.000 claims 1
- YILVWNABBHMIST-UHFFFAOYSA-N n-cyclopropyl-3-[6-[2-(4-hydroxypiperidin-1-yl)ethoxy]-4-oxoquinazolin-3-yl]-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C(C1=C2)=O)C=NC1=CC=C2OCCN1CCC(O)CC1 YILVWNABBHMIST-UHFFFAOYSA-N 0.000 claims 1
- UNJJXYGJEIHFHT-UHFFFAOYSA-N n-cyclopropyl-3-[6-[2-(dimethylamino)-2-methylpropoxy]-4-oxoquinazolin-3-yl]-4-methylbenzamide Chemical compound O=C1C2=CC(OCC(C)(C)N(C)C)=CC=C2N=CN1C(C(=CC=1)C)=CC=1C(=O)NC1CC1 UNJJXYGJEIHFHT-UHFFFAOYSA-N 0.000 claims 1
- VLTCTDVFMHDSMX-UHFFFAOYSA-N n-cyclopropyl-3-[6-[2-(dimethylamino)-2-oxoethoxy]-4-oxoquinazolin-3-yl]-4-methylbenzamide Chemical compound O=C1C2=CC(OCC(=O)N(C)C)=CC=C2N=CN1C(C(=CC=1)C)=CC=1C(=O)NC1CC1 VLTCTDVFMHDSMX-UHFFFAOYSA-N 0.000 claims 1
- WZMLJWAUXHYMRE-UHFFFAOYSA-N n-cyclopropyl-3-[6-[2-(dimethylamino)ethoxy]-4-oxoquinazolin-3-yl]-4-methylbenzamide Chemical compound O=C1C2=CC(OCCN(C)C)=CC=C2N=CN1C(C(=CC=1)C)=CC=1C(=O)NC1CC1 WZMLJWAUXHYMRE-UHFFFAOYSA-N 0.000 claims 1
- BVEHSYQNIRZTDN-UHFFFAOYSA-N n-cyclopropyl-3-[6-[2-(methanesulfonamido)ethoxy]-4-oxoquinazolin-3-yl]-4-methylbenzamide Chemical compound C1=C(N2C(C3=CC(OCCNS(C)(=O)=O)=CC=C3N=C2)=O)C(C)=CC=C1C(=O)NC1CC1 BVEHSYQNIRZTDN-UHFFFAOYSA-N 0.000 claims 1
- NALFVCKYTFAUMJ-FQEVSTJZSA-N n-cyclopropyl-3-[6-[2-[(2s)-2-(hydroxymethyl)pyrrolidin-1-yl]ethoxy]-4-oxoquinazolin-3-yl]-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C(C1=C2)=O)C=NC1=CC=C2OCCN1CCC[C@H]1CO NALFVCKYTFAUMJ-FQEVSTJZSA-N 0.000 claims 1
- BULRNDVFABOUKN-GOSISDBHSA-N n-cyclopropyl-3-[6-[2-[(3r)-3-fluoropyrrolidin-1-yl]ethoxy]-4-oxoquinazolin-3-yl]-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C(C1=C2)=O)C=NC1=CC=C2OCCN1CC[C@@H](F)C1 BULRNDVFABOUKN-GOSISDBHSA-N 0.000 claims 1
- GCCCHFAPYLFBIP-UHFFFAOYSA-N n-cyclopropyl-3-[6-[2-[2-methoxyethyl(methyl)amino]ethoxy]-4-oxoquinazolin-3-yl]-4-methylbenzamide Chemical compound O=C1C2=CC(OCCN(C)CCOC)=CC=C2N=CN1C(C(=CC=1)C)=CC=1C(=O)NC1CC1 GCCCHFAPYLFBIP-UHFFFAOYSA-N 0.000 claims 1
- FQAWJBPEQOKZKV-UHFFFAOYSA-N n-cyclopropyl-3-[6-[2-[2-methoxyethyl(propan-2-yl)amino]ethoxy]-4-oxoquinazolin-3-yl]-4-methylbenzamide Chemical compound O=C1C2=CC(OCCN(CCOC)C(C)C)=CC=C2N=CN1C(C(=CC=1)C)=CC=1C(=O)NC1CC1 FQAWJBPEQOKZKV-UHFFFAOYSA-N 0.000 claims 1
- YRPFIINFPFURQB-UHFFFAOYSA-N n-cyclopropyl-3-[6-[3-(4-hydroxypiperidin-1-yl)propoxy]-4-oxoquinazolin-3-yl]-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C(C1=C2)=O)C=NC1=CC=C2OCCCN1CCC(O)CC1 YRPFIINFPFURQB-UHFFFAOYSA-N 0.000 claims 1
- AIEXXVAQFFNMSW-UHFFFAOYSA-N n-cyclopropyl-3-[6-[3-(dimethylamino)-2-methylpropoxy]-4-oxoquinazolin-3-yl]-4-methylbenzamide Chemical compound O=C1C2=CC(OCC(C)CN(C)C)=CC=C2N=CN1C(C(=CC=1)C)=CC=1C(=O)NC1CC1 AIEXXVAQFFNMSW-UHFFFAOYSA-N 0.000 claims 1
- PTHMAPUKXHBKAQ-UHFFFAOYSA-N n-cyclopropyl-3-[6-[3-(dimethylamino)prop-1-ynyl]-4-oxoquinazolin-3-yl]-4-methylbenzamide Chemical compound O=C1C2=CC(C#CCN(C)C)=CC=C2N=CN1C(C(=CC=1)C)=CC=1C(=O)NC1CC1 PTHMAPUKXHBKAQ-UHFFFAOYSA-N 0.000 claims 1
- HUPOHVVZLQCIHD-UHFFFAOYSA-N n-cyclopropyl-3-[6-[3-(dimethylamino)propoxy]-4-oxoquinazolin-3-yl]-4-methylbenzamide Chemical compound O=C1C2=CC(OCCCN(C)C)=CC=C2N=CN1C(C(=CC=1)C)=CC=1C(=O)NC1CC1 HUPOHVVZLQCIHD-UHFFFAOYSA-N 0.000 claims 1
- MOOJSSXTRRYSSV-UHFFFAOYSA-N n-cyclopropyl-3-[6-[3-(dimethylamino)propyl]-4-oxoquinazolin-3-yl]-4-methylbenzamide Chemical compound O=C1C2=CC(CCCN(C)C)=CC=C2N=CN1C(C(=CC=1)C)=CC=1C(=O)NC1CC1 MOOJSSXTRRYSSV-UHFFFAOYSA-N 0.000 claims 1
- NAPWLNDHTWMGDU-HXUWFJFHSA-N n-cyclopropyl-3-[6-[3-[(3r)-3-hydroxypyrrolidin-1-yl]propoxy]-4-oxoquinazolin-3-yl]-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C(C1=C2)=O)C=NC1=CC=C2OCCCN1CC[C@@H](O)C1 NAPWLNDHTWMGDU-HXUWFJFHSA-N 0.000 claims 1
- DCTLMKOJXVEGLY-UHFFFAOYSA-N n-cyclopropyl-3-[6-[3-[2-methoxyethyl(methyl)amino]propoxy]-4-oxoquinazolin-3-yl]-4-methylbenzamide Chemical compound O=C1C2=CC(OCCCN(C)CCOC)=CC=C2N=CN1C(C(=CC=1)C)=CC=1C(=O)NC1CC1 DCTLMKOJXVEGLY-UHFFFAOYSA-N 0.000 claims 1
- LZBUHCGCJAQJSK-UHFFFAOYSA-N n-cyclopropyl-3-[6-[3-[furan-3-ylmethyl(methyl)amino]propoxy]-4-oxoquinazolin-3-yl]-4-methylbenzamide Chemical compound C1=COC=C1CN(C)CCCOC(C=C1C2=O)=CC=C1N=CN2C(C(=CC=1)C)=CC=1C(=O)NC1CC1 LZBUHCGCJAQJSK-UHFFFAOYSA-N 0.000 claims 1
- UYAJLWQZRUSGFX-UHFFFAOYSA-N n-cyclopropyl-3-[6-[4-(2,2-difluoroethyl)piperazin-1-yl]-4-oxoquinazolin-3-yl]-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C(C1=C2)=O)C=NC1=CC=C2N1CCN(CC(F)F)CC1 UYAJLWQZRUSGFX-UHFFFAOYSA-N 0.000 claims 1
- BZJHTYFLENHXOG-UHFFFAOYSA-N n-cyclopropyl-3-[6-[4-(2-ethoxyethyl)piperazin-1-yl]-4-oxoquinazolin-3-yl]-4-methylbenzamide Chemical compound C1CN(CCOCC)CCN1C1=CC=C(N=CN(C=2C(=CC=C(C=2)C(=O)NC2CC2)C)C2=O)C2=C1 BZJHTYFLENHXOG-UHFFFAOYSA-N 0.000 claims 1
- MWTWUHRLTPWZKJ-UHFFFAOYSA-N n-cyclopropyl-3-[6-[4-(2-fluoroethyl)piperazin-1-yl]-4-oxoquinazolin-3-yl]-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C(C1=C2)=O)C=NC1=CC=C2N1CCN(CCF)CC1 MWTWUHRLTPWZKJ-UHFFFAOYSA-N 0.000 claims 1
- UHYQZJQHXRIRLA-UHFFFAOYSA-N n-cyclopropyl-3-[6-[4-(2-methoxyethyl)-1,4-diazepan-1-yl]-4-oxoquinazolin-3-yl]-4-methylbenzamide Chemical compound C1CN(CCOC)CCCN1C1=CC=C(N=CN(C=2C(=CC=C(C=2)C(=O)NC2CC2)C)C2=O)C2=C1 UHYQZJQHXRIRLA-UHFFFAOYSA-N 0.000 claims 1
- LPSJUPVADXIZEL-UHFFFAOYSA-N n-cyclopropyl-3-[6-[4-(cyclopropylmethyl)-1,4-diazepan-1-yl]-4-oxoquinazolin-3-yl]-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C(C1=C2)=O)C=NC1=CC=C2N(CC1)CCCN1CC1CC1 LPSJUPVADXIZEL-UHFFFAOYSA-N 0.000 claims 1
- RDBLFXLOUSXOMI-UHFFFAOYSA-N n-cyclopropyl-3-[6-[4-(cyclopropylmethyl)piperazin-1-yl]-4-oxoquinazolin-3-yl]-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C(C1=C2)=O)C=NC1=CC=C2N(CC1)CCN1CC1CC1 RDBLFXLOUSXOMI-UHFFFAOYSA-N 0.000 claims 1
- XQWFURUWHYNGHP-IBGZPJMESA-N n-cyclopropyl-3-[6-[[(2s)-1-(2-hydroxyacetyl)pyrrolidin-2-yl]methoxy]-4-oxoquinazolin-3-yl]-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C(C1=C2)=O)C=NC1=CC=C2OC[C@@H]1CCCN1C(=O)CO XQWFURUWHYNGHP-IBGZPJMESA-N 0.000 claims 1
- QPEFSEABPBXXRC-UHFFFAOYSA-N n-cyclopropyl-3-[7-[3-(dimethylamino)propoxy]-4-oxoquinazolin-3-yl]-4-methylbenzamide Chemical compound C=1C(OCCCN(C)C)=CC=C(C2=O)C=1N=CN2C(C(=CC=1)C)=CC=1C(=O)NC1CC1 QPEFSEABPBXXRC-UHFFFAOYSA-N 0.000 claims 1
- IJHTWCMNEATOKW-UHFFFAOYSA-N n-cyclopropyl-3-[7-fluoro-6-(4-methylpiperazin-1-yl)-4-oxoquinazolin-3-yl]-4-methylbenzamide Chemical compound C1CN(C)CCN1C1=CC(C(N(C=2C(=CC=C(C=2)C(=O)NC2CC2)C)C=N2)=O)=C2C=C1F IJHTWCMNEATOKW-UHFFFAOYSA-N 0.000 claims 1
- MCOWZHSLKWSKEH-UHFFFAOYSA-N n-cyclopropyl-4-methyl-3-(4-oxopyrido[2,3-d]pyrimidin-3-yl)benzamide Chemical compound C1=C(N2C(C3=CC=CN=C3N=C2)=O)C(C)=CC=C1C(=O)NC1CC1 MCOWZHSLKWSKEH-UHFFFAOYSA-N 0.000 claims 1
- SOAHBBABXLMJLH-UHFFFAOYSA-N n-cyclopropyl-4-methyl-3-(4-oxoquinazolin-3-yl)benzamide Chemical compound C1=C(N2C(C3=CC=CC=C3N=C2)=O)C(C)=CC=C1C(=O)NC1CC1 SOAHBBABXLMJLH-UHFFFAOYSA-N 0.000 claims 1
- OTDUFFFEGBCDJS-UHFFFAOYSA-N n-cyclopropyl-4-methyl-3-[4-oxo-6-(1,2,3,6-tetrahydropyridin-4-yl)quinazolin-3-yl]benzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C(C1=C2)=O)C=NC1=CC=C2C1=CCNCC1 OTDUFFFEGBCDJS-UHFFFAOYSA-N 0.000 claims 1
- XCYYMGHNWCHXJP-UHFFFAOYSA-N n-cyclopropyl-4-methyl-3-[4-oxo-6-(1-propan-2-ylpiperidin-4-yl)oxyquinazolin-3-yl]benzamide Chemical compound C1CN(C(C)C)CCC1OC1=CC=C(N=CN(C=2C(=CC=C(C=2)C(=O)NC2CC2)C)C2=O)C2=C1 XCYYMGHNWCHXJP-UHFFFAOYSA-N 0.000 claims 1
- VLGXXQVHZLRUHZ-UHFFFAOYSA-N n-cyclopropyl-4-methyl-3-[4-oxo-6-(1-propan-2-ylpyrrolidin-3-yl)oxyquinazolin-3-yl]benzamide Chemical compound C1N(C(C)C)CCC1OC1=CC=C(N=CN(C=2C(=CC=C(C=2)C(=O)NC2CC2)C)C2=O)C2=C1 VLGXXQVHZLRUHZ-UHFFFAOYSA-N 0.000 claims 1
- BPJSFEFKWJGWQZ-UHFFFAOYSA-N n-cyclopropyl-4-methyl-3-[4-oxo-6-(2-piperidin-1-ylethoxy)quinazolin-3-yl]benzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C(C1=C2)=O)C=NC1=CC=C2OCCN1CCCCC1 BPJSFEFKWJGWQZ-UHFFFAOYSA-N 0.000 claims 1
- YFNXUYXKQNOZHH-UHFFFAOYSA-N n-cyclopropyl-4-methyl-3-[4-oxo-6-(3-thiomorpholin-4-ylpropoxy)quinazolin-3-yl]benzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C(C1=C2)=O)C=NC1=CC=C2OCCCN1CCSCC1 YFNXUYXKQNOZHH-UHFFFAOYSA-N 0.000 claims 1
- LTEZBUKUKJFLGM-UHFFFAOYSA-N n-cyclopropyl-4-methyl-3-[4-oxo-6-(4-propyl-1,4-diazepan-1-yl)quinazolin-3-yl]benzamide Chemical compound C1CN(CCC)CCCN1C1=CC=C(N=CN(C=2C(=CC=C(C=2)C(=O)NC2CC2)C)C2=O)C2=C1 LTEZBUKUKJFLGM-UHFFFAOYSA-N 0.000 claims 1
- VLGXXQVHZLRUHZ-OAQYLSRUSA-N n-cyclopropyl-4-methyl-3-[4-oxo-6-[(3r)-1-propan-2-ylpyrrolidin-3-yl]oxyquinazolin-3-yl]benzamide Chemical compound C1N(C(C)C)CC[C@H]1OC1=CC=C(N=CN(C=2C(=CC=C(C=2)C(=O)NC2CC2)C)C2=O)C2=C1 VLGXXQVHZLRUHZ-OAQYLSRUSA-N 0.000 claims 1
- HBCJIPTVFWQTKZ-GOSISDBHSA-N n-cyclopropyl-4-methyl-3-[4-oxo-6-[(3r)-pyrrolidin-3-yl]oxyquinazolin-3-yl]benzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C(C1=C2)=O)C=NC1=CC=C2O[C@@H]1CCNC1 HBCJIPTVFWQTKZ-GOSISDBHSA-N 0.000 claims 1
- VLGXXQVHZLRUHZ-NRFANRHFSA-N n-cyclopropyl-4-methyl-3-[4-oxo-6-[(3s)-1-propan-2-ylpyrrolidin-3-yl]oxyquinazolin-3-yl]benzamide Chemical compound C1N(C(C)C)CC[C@@H]1OC1=CC=C(N=CN(C=2C(=CC=C(C=2)C(=O)NC2CC2)C)C2=O)C2=C1 VLGXXQVHZLRUHZ-NRFANRHFSA-N 0.000 claims 1
- HBCJIPTVFWQTKZ-SFHVURJKSA-N n-cyclopropyl-4-methyl-3-[4-oxo-6-[(3s)-pyrrolidin-3-yl]oxyquinazolin-3-yl]benzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C(C1=C2)=O)C=NC1=CC=C2O[C@H]1CCNC1 HBCJIPTVFWQTKZ-SFHVURJKSA-N 0.000 claims 1
- LLRVCGMBTPAADF-UHFFFAOYSA-N n-cyclopropyl-4-methyl-3-[4-oxo-6-[2-(4-propan-2-ylpiperazin-1-yl)ethoxy]quinazolin-3-yl]benzamide Chemical compound C1CN(C(C)C)CCN1CCOC1=CC=C(N=CN(C=2C(=CC=C(C=2)C(=O)NC2CC2)C)C2=O)C2=C1 LLRVCGMBTPAADF-UHFFFAOYSA-N 0.000 claims 1
- SYOFKBZUDVYPMI-GOSISDBHSA-N n-cyclopropyl-4-methyl-3-[4-oxo-6-[[(2r)-pyrrolidin-2-yl]methoxy]quinazolin-3-yl]benzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C(C1=C2)=O)C=NC1=CC=C2OC[C@H]1CCCN1 SYOFKBZUDVYPMI-GOSISDBHSA-N 0.000 claims 1
- SYOFKBZUDVYPMI-SFHVURJKSA-N n-cyclopropyl-4-methyl-3-[4-oxo-6-[[(2s)-pyrrolidin-2-yl]methoxy]quinazolin-3-yl]benzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C(C1=C2)=O)C=NC1=CC=C2OC[C@@H]1CCCN1 SYOFKBZUDVYPMI-SFHVURJKSA-N 0.000 claims 1
- JKJWTTZRIOTRFG-UHFFFAOYSA-N n-cyclopropyl-4-methyl-3-[6-(1-methyl-3,6-dihydro-2h-pyridin-4-yl)-4-oxoquinazolin-3-yl]benzamide Chemical compound C1N(C)CCC(C=2C=C3C(=O)N(C=4C(=CC=C(C=4)C(=O)NC4CC4)C)C=NC3=CC=2)=C1 JKJWTTZRIOTRFG-UHFFFAOYSA-N 0.000 claims 1
- FBMVCNHYMNJXAY-UHFFFAOYSA-N n-cyclopropyl-4-methyl-3-[6-(1-methylpiperidin-4-yl)-4-oxoquinazolin-3-yl]benzamide Chemical compound C1CN(C)CCC1C1=CC=C(N=CN(C=2C(=CC=C(C=2)C(=O)NC2CC2)C)C2=O)C2=C1 FBMVCNHYMNJXAY-UHFFFAOYSA-N 0.000 claims 1
- ABUCQWIMRCIACF-UHFFFAOYSA-N n-cyclopropyl-4-methyl-3-[6-(1-methylpyrrolidin-3-yl)oxy-4-oxoquinazolin-3-yl]benzamide Chemical compound C1N(C)CCC1OC1=CC=C(N=CN(C=2C(=CC=C(C=2)C(=O)NC2CC2)C)C2=O)C2=C1 ABUCQWIMRCIACF-UHFFFAOYSA-N 0.000 claims 1
- VFLHHNVMMXWEIN-UHFFFAOYSA-N n-cyclopropyl-4-methyl-3-[6-(2-methylpropoxy)-4-oxoquinazolin-3-yl]benzamide Chemical compound O=C1C2=CC(OCC(C)C)=CC=C2N=CN1C(C(=CC=1)C)=CC=1C(=O)NC1CC1 VFLHHNVMMXWEIN-UHFFFAOYSA-N 0.000 claims 1
- GBJMTGFASGSXMF-LJQANCHMSA-N n-cyclopropyl-4-methyl-3-[6-[(3r)-3-methyl-4-propan-2-ylpiperazin-1-yl]-4-oxoquinazolin-3-yl]benzamide Chemical compound C1[C@@H](C)N(C(C)C)CCN1C1=CC=C(N=CN(C=2C(=CC=C(C=2)C(=O)NC2CC2)C)C2=O)C2=C1 GBJMTGFASGSXMF-LJQANCHMSA-N 0.000 claims 1
- YCEUSQOBFTYJBM-UHFFFAOYSA-N n-cyclopropyl-4-methyl-3-[6-[2-(1,4-oxazepan-4-yl)ethoxy]-4-oxoquinazolin-3-yl]benzamide Chemical compound CC1=CC=C(C(=O)NC2CC2)C=C1N(C(C1=C2)=O)C=NC1=CC=C2OCCN1CCCOCC1 YCEUSQOBFTYJBM-UHFFFAOYSA-N 0.000 claims 1
- LSDZMJLGZRWFCP-UHFFFAOYSA-N n-cyclopropyl-4-methyl-3-[6-[2-[methyl(propan-2-yl)amino]ethoxy]-4-oxoquinazolin-3-yl]benzamide Chemical compound O=C1C2=CC(OCCN(C)C(C)C)=CC=C2N=CN1C(C(=CC=1)C)=CC=1C(=O)NC1CC1 LSDZMJLGZRWFCP-UHFFFAOYSA-N 0.000 claims 1
- NBEPQTPCNUXMLE-LJQANCHMSA-N n-cyclopropyl-4-methyl-3-[6-[[(2r)-1-methylpyrrolidin-2-yl]methoxy]-4-oxoquinazolin-3-yl]benzamide Chemical compound CN1CCC[C@@H]1COC1=CC=C(N=CN(C=2C(=CC=C(C=2)C(=O)NC2CC2)C)C2=O)C2=C1 NBEPQTPCNUXMLE-LJQANCHMSA-N 0.000 claims 1
- NBEPQTPCNUXMLE-IBGZPJMESA-N n-cyclopropyl-4-methyl-3-[6-[[(2s)-1-methylpyrrolidin-2-yl]methoxy]-4-oxoquinazolin-3-yl]benzamide Chemical compound CN1CCC[C@H]1COC1=CC=C(N=CN(C=2C(=CC=C(C=2)C(=O)NC2CC2)C)C2=O)C2=C1 NBEPQTPCNUXMLE-IBGZPJMESA-N 0.000 claims 1
- RTQVLYIEJIWJSW-UHFFFAOYSA-N n-cyclopropyl-4-methyl-3-[7-(4-methylpiperazin-1-yl)-4-oxoquinazolin-3-yl]benzamide Chemical compound C1CN(C)CCN1C1=CC=C2C(=O)N(C=3C(=CC=C(C=3)C(=O)NC3CC3)C)C=NC2=C1 RTQVLYIEJIWJSW-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- FQJRZOYTUCCBQR-UHFFFAOYSA-N tert-butyl 2-methylheptanoate Chemical compound CCCCCC(C)C(=O)OC(C)(C)C FQJRZOYTUCCBQR-UHFFFAOYSA-N 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 description 7
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 6
- 125000002757 morpholinyl group Chemical group 0.000 description 5
- 125000004193 piperazinyl group Chemical group 0.000 description 5
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 125000004655 dihydropyridinyl group Chemical group N1(CC=CC=C1)* 0.000 description 4
- 125000005053 dihydropyrimidinyl group Chemical group N1(CN=CC=C1)* 0.000 description 4
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 4
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000029936 alkylation Effects 0.000 description 3
- 238000005804 alkylation reaction Methods 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 125000001769 aryl amino group Chemical group 0.000 description 3
- 125000004104 aryloxy group Chemical group 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 239000003701 inert diluent Substances 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 235000010650 Hyssopus officinalis Nutrition 0.000 description 2
- 240000001812 Hyssopus officinalis Species 0.000 description 2
- 241001024304 Mino Species 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- 239000012442 inert solvent Substances 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- RWZYAGGXGHYGMB-UHFFFAOYSA-N anthranilic acid Chemical class NC1=CC=CC=C1C(O)=O RWZYAGGXGHYGMB-UHFFFAOYSA-N 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000001499 aryl bromides Chemical class 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- FDPIMTJIUBPUKL-UHFFFAOYSA-N dimethylacetone Natural products CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 125000005415 substituted alkoxy group Chemical group 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 229910052717 sulfur Chemical group 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0324790.5A GB0324790D0 (en) | 2003-10-24 | 2003-10-24 | Amide derivatives |
| GB0324790.5 | 2003-10-24 | ||
| PCT/GB2004/004474 WO2005042502A1 (en) | 2003-10-24 | 2004-10-22 | Amide derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007509118A JP2007509118A (ja) | 2007-04-12 |
| JP2007509118A5 true JP2007509118A5 (enExample) | 2007-11-29 |
| JP4987478B2 JP4987478B2 (ja) | 2012-07-25 |
Family
ID=29595715
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006536171A Expired - Fee Related JP4987478B2 (ja) | 2003-10-24 | 2004-10-22 | アミド誘導体 |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US7750154B2 (enExample) |
| EP (1) | EP1682520B1 (enExample) |
| JP (1) | JP4987478B2 (enExample) |
| KR (1) | KR101127697B1 (enExample) |
| CN (2) | CN103012376A (enExample) |
| AR (1) | AR046308A1 (enExample) |
| AT (1) | ATE499347T1 (enExample) |
| AU (1) | AU2004285749B2 (enExample) |
| BR (1) | BRPI0415746A (enExample) |
| CA (1) | CA2543351C (enExample) |
| DE (1) | DE602004031543D1 (enExample) |
| ES (1) | ES2359409T3 (enExample) |
| GB (1) | GB0324790D0 (enExample) |
| IL (1) | IL175065A (enExample) |
| IS (1) | IS8450A (enExample) |
| MX (1) | MXPA06004465A (enExample) |
| MY (1) | MY140729A (enExample) |
| NO (1) | NO20062370L (enExample) |
| NZ (1) | NZ547095A (enExample) |
| RU (1) | RU2375352C2 (enExample) |
| SA (1) | SA04250351B1 (enExample) |
| SG (1) | SG147409A1 (enExample) |
| TW (1) | TWI343378B (enExample) |
| UA (1) | UA83867C2 (enExample) |
| UY (1) | UY28578A1 (enExample) |
| WO (1) | WO2005042502A1 (enExample) |
| ZA (1) | ZA200603226B (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2260007C2 (ru) | 1999-03-17 | 2005-09-10 | Астразенека Аб | Производные амида, способ их получения (варианты), фармацевтическая композиция, способ ингибирования |
| GB0329572D0 (en) | 2003-12-20 | 2004-01-28 | Astrazeneca Ab | Amide derivatives |
| US20050261278A1 (en) | 2004-05-21 | 2005-11-24 | Weiner David M | Selective serotonin receptor inverse agonists as therapeutics for disease |
| AU2006205066B2 (en) | 2005-01-10 | 2012-05-17 | Acadia Pharmaceuticals Inc. | Aminophenyl derivatives as selective androgen receptor modulators |
| GB0504019D0 (en) | 2005-02-26 | 2005-04-06 | Astrazeneca Ab | Amide derivatives |
| GB0516570D0 (en) * | 2005-08-12 | 2005-09-21 | Astrazeneca Ab | Amide derivatives |
| US20100234355A1 (en) * | 2006-06-19 | 2010-09-16 | Barrie Martin | Isoquinoline derivatives and their use as inhibitors of cytokine mediated diseases |
| GB0702456D0 (en) | 2007-02-08 | 2007-03-21 | Astrazeneca Ab | New combination |
| AU2008229383B2 (en) * | 2007-03-20 | 2013-09-05 | Celgene Corporation | 4'-O-substituted isoindoline derivatives and compositions comprising and methods of using the same |
| US8354417B2 (en) * | 2007-09-26 | 2013-01-15 | Celgene Corporation | Solid forms comprising 3-(2,5-dimethyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione, compositions comprising the same, and methods of using the same |
| CA2704710C (en) * | 2007-09-26 | 2016-02-02 | Celgene Corporation | 6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising the same |
| JP2011503232A (ja) | 2007-11-20 | 2011-01-27 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド | 免疫応答の調節 |
| WO2009138778A1 (en) * | 2008-05-12 | 2009-11-19 | Astrazeneca Ab | Cyclopropyl benzamide derivatives as intermediates for cytokine inhibitors |
| WO2009151910A2 (en) * | 2008-05-25 | 2009-12-17 | Wyeth | Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer |
| WO2011010131A1 (en) | 2009-07-21 | 2011-01-27 | Astrazeneca Ab | Compositions comprising an oxoisoquinoline methylbenzamide and a polymer |
| GB0913345D0 (en) | 2009-07-31 | 2009-09-16 | Astrazeneca Ab | New combination 802 |
| WO2011061527A1 (en) | 2009-11-17 | 2011-05-26 | Astrazeneca Ab | Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases |
| WO2011073662A1 (en) | 2009-12-17 | 2011-06-23 | Astrazeneca Ab | Combination of a benzoxazinone and a further agent for treating respiratory diseases |
| US9296722B2 (en) | 2010-05-27 | 2016-03-29 | Ambit Biosciences Corporation | Azolyl urea compounds and methods of use thereof |
| GB201021992D0 (en) | 2010-12-23 | 2011-02-02 | Astrazeneca Ab | Compound |
| GB201021979D0 (en) | 2010-12-23 | 2011-02-02 | Astrazeneca Ab | New compound |
| SI2861566T1 (sl) | 2012-06-13 | 2017-03-31 | F. Hoffmann-La Roche Ag | Novi diazaspirocikloalkan in azaspirocikloalkan |
| DK2900669T3 (da) | 2012-09-25 | 2019-11-04 | Hoffmann La Roche | Hexahydropyrrolo[3,4-C]pyrrolderivater og relaterede forbindelser som autotaxin (ATX)-inhibitorer og som inhibitorer af lysophosphatidsyre (LPA)-produktion til behandling af f.eks. nyresygdomme |
| AR095079A1 (es) | 2013-03-12 | 2015-09-16 | Hoffmann La Roche | Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo |
| JP6496730B2 (ja) | 2013-11-26 | 2019-04-03 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 新規なオクタヒドロ−シクロブタ［１，２−ｃ；３，４−ｃ’］ジピロール−２−イル |
| AU2015238541B2 (en) | 2014-03-26 | 2019-09-19 | F. Hoffmann-La Roche Ag | Condensed [1,4]diazepine compounds as autotaxin (ATX) and lysophosphatidic acid (LPA) production inhibitors |
| CN106103446B (zh) | 2014-03-26 | 2019-07-30 | 豪夫迈·罗氏有限公司 | 作为自分泌运动因子(atx)和溶血磷脂酸(lpa)生产抑制剂的二环化合物 |
| JP6038212B2 (ja) * | 2015-03-18 | 2016-12-07 | ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ | 甲状腺刺激ホルモン受容体（ｔｓｈｒ）の低分子量アゴニスト |
| EP3274053A4 (en) | 2015-03-23 | 2018-12-05 | The Brigham and Women's Hospital, Inc. | Tolerogenic nanoparticles for treating diabetes mellitus |
| MA41898A (fr) | 2015-04-10 | 2018-02-13 | Hoffmann La Roche | Dérivés de quinazolinone bicyclique |
| US9957267B2 (en) | 2015-07-01 | 2018-05-01 | Crinetics Pharmaceuticals, Inc. | Somatostatin modulators and uses thereof |
| KR20180043837A (ko) | 2015-09-04 | 2018-04-30 | 에프. 호프만-라 로슈 아게 | 페녹시메틸 유도체 |
| RU2018114289A (ru) | 2015-09-24 | 2019-10-24 | Ф. Хоффманн-Ля Рош Аг | Бициклические соединения в качестве ингибиторов аутотаксина (atx) |
| EP3353181B1 (en) | 2015-09-24 | 2021-08-11 | F. Hoffmann-La Roche AG | Bicyclic compounds as dual atx/ca inhibitors |
| MX2018001890A (es) | 2015-09-24 | 2018-06-20 | Hoffmann La Roche | Compuestos biciclicos como inhibidores de autotaxina (atx). |
| EP3353178B1 (en) | 2015-09-24 | 2021-07-14 | F. Hoffmann-La Roche AG | Bicyclic compounds as dual atx/ca inhibitors |
| JP7090099B2 (ja) | 2017-03-16 | 2022-06-23 | エフ．ホフマン－ラ ロシュ アーゲー | Ａｔｘインヒビターとしての新規二環式化合物 |
| CR20190423A (es) | 2017-03-16 | 2019-11-01 | Hoffmann La Roche | Nuevos compuestos biciclícos como inhibidores dobles de atx/ca |
| CN106977500A (zh) * | 2017-04-17 | 2017-07-25 | 牡丹江医学院 | 一种用于治疗脑梗塞的药物及其制备方法 |
| US11028068B2 (en) | 2017-07-25 | 2021-06-08 | Crinetics Pharmaceuticals, Inc. | Somatostatin modulators and uses thereof |
| BR112022020423A2 (pt) * | 2020-04-08 | 2022-11-29 | Remix Therapeutics Inc | Compostos e métodos para modulação de splicing |
| US12180193B2 (en) | 2020-08-28 | 2024-12-31 | Arvinas Operations, Inc. | Accelerating fibrosarcoma protein degrading compounds and associated methods of use |
| EP4584258A1 (en) | 2022-09-07 | 2025-07-16 | Arvinas Operations, Inc. | Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1903899A (en) | 1933-04-18 | Cabboxylic acid abylides oe the benzene sebies and process oe making | ||
| DE522788C (de) | 1928-11-01 | 1931-04-15 | I G Farbenindustrie Akt Ges | Verfahren zur Darstellung von Carbonsaeurearyliden der Benzolreihe |
| US1909960A (en) | 1929-08-06 | 1933-05-23 | Du Pont | Intermediate for azo dyes |
| NL272900A (enExample) | 1960-12-23 | |||
| US3755332A (en) | 1971-07-01 | 1973-08-28 | Ciba Geigy Corp | Substituted 4 indazolaminoquinolines |
| DE2812252A1 (de) | 1978-03-21 | 1979-10-04 | Bayer Ag | 1,2,4-triazol-blockierte polyisocyanate als vernetzer fuer lackbindemittel |
| US4367328A (en) | 1981-03-05 | 1983-01-04 | The Dow Chemical Company | Epoxy resins from hydroxy benzamides |
| US4524168A (en) | 1981-11-18 | 1985-06-18 | Ciba-Geigy Corporation | Process for the mass coloration of polymers |
| ZA85187B (en) * | 1984-01-09 | 1986-08-27 | Janssen Pharmaceutica Nv | 4-((bicyclic heterocyclyl)-methyl and-hetero)-piperidines |
| US4749729A (en) | 1984-06-21 | 1988-06-07 | American Cyanamid Company | Epoxy resin compositions curable above 160 F. and below 250 F. |
| JPS61204221A (ja) | 1985-03-07 | 1986-09-10 | Hitachi Chem Co Ltd | 熱硬化性樹脂組成物 |
| US5710158A (en) | 1991-05-10 | 1998-01-20 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
| AU2552492A (en) | 1991-08-23 | 1993-03-16 | United States of America as represented by The Secretary Department of Health and Human Services, The | Raf protein kinase therapeutics |
| US7772432B2 (en) * | 1991-09-19 | 2010-08-10 | Astrazeneca Ab | Amidobenzamide derivatives which are useful as cytokine inhibitors |
| GB9816837D0 (en) | 1998-08-04 | 1998-09-30 | Zeneca Ltd | Amide derivatives |
| AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| GB9314884D0 (en) | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Tricyclic derivatives |
| IL112249A (en) | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| US5550132A (en) | 1994-06-22 | 1996-08-27 | University Of North Carolina | Hydroxyalkylammonium-pyrimidines or purines and nucleoside derivatives, useful as inhibitors of inflammatory cytokines |
| CA2228050A1 (en) | 1995-08-10 | 1997-02-20 | Harold G. Selnick | 2,5-substituted aryl pyrroles, compositions containing such compounds and methods of use |
| EP0849256B1 (en) | 1995-08-22 | 2005-06-08 | Japan Tobacco Inc. | Amide compounds and use of the same |
| AR004010A1 (es) | 1995-10-11 | 1998-09-30 | Glaxo Group Ltd | Compuestos heterociclicos |
| GB9604926D0 (en) | 1996-03-08 | 1996-05-08 | Sandoz Ltd | Organic compounds |
| JP2000506532A (ja) | 1996-03-13 | 2000-05-30 | スミスクライン・ビーチャム・コーポレイション | サイトカイン介在疾患の治療にて有用な新規ピリミジン化合物 |
| JP2001506230A (ja) | 1996-08-09 | 2001-05-15 | スミスクライン・ビーチャム・コーポレイション | 新規ピペラジン含有化合物 |
| GB9623833D0 (en) | 1996-11-16 | 1997-01-08 | Zeneca Ltd | Chemical compound |
| US6103737A (en) | 1997-07-03 | 2000-08-15 | Dupont Pharmaceuticals Company | Aryl- and arylamino- substituted heterocycles as corticotropin releasing hormone antagonists |
| ZA986732B (en) | 1997-07-29 | 1999-02-02 | Warner Lambert Co | Irreversible inhibitiors of tyrosine kinases |
| DK1017378T3 (da) | 1997-09-23 | 2003-03-17 | Astrazeneca Ab | Amidderivater til behandling af sygdomme medieret af cytokiner |
| EP0945443B9 (en) | 1998-03-27 | 2003-08-13 | Janssen Pharmaceutica N.V. | HIV inhibiting pyrimidine derivatives |
| ES2232137T3 (es) | 1998-05-15 | 2005-05-16 | Astrazeneca Ab | Derivados de benzamida para el tratamiento de enfermedades mediadas por citoquinas. |
| WO1999059960A1 (en) | 1998-05-15 | 1999-11-25 | Astrazeneca Ab | Benzamide derivatives for the treatment of diseases mediated by cytokines |
| PL345817A1 (en) | 1998-08-04 | 2002-01-14 | Astrazeneca Ab | Amide derivatives useful as inhibitors of the production of cytokines |
| WO2000012487A1 (en) | 1998-08-27 | 2000-03-09 | Sumitomo Pharmaceuticals Co., Ltd. | Pyrimidine derivatives |
| WO2000012486A1 (en) | 1998-08-29 | 2000-03-09 | Astrazeneca Ab | Pyrimidine compounds |
| JP2002523497A (ja) | 1998-08-29 | 2002-07-30 | アストラゼネカ・アクチエボラーグ | ピリミジン化合物 |
| DK1115707T3 (da) | 1998-09-25 | 2004-03-01 | Astrazeneca Ab | Benzamidderivater og deres anvendelse som cytokininhibitorer |
| DE69905264T2 (de) * | 1998-10-01 | 2003-12-11 | Astrazeneca Ab, Soedertaelje | Chinolin- und chinazolin derivate und ihre verwendung als inhibitoren von krankheiten, bei denen cytokine beteiligt wird |
| RU2260007C2 (ru) * | 1999-03-17 | 2005-09-10 | Астразенека Аб | Производные амида, способ их получения (варианты), фармацевтическая композиция, способ ингибирования |
| KR20010110668A (ko) | 1999-03-17 | 2001-12-13 | 다비드 에 질레스 | 아미드 유도체 |
| GB9906566D0 (en) | 1999-03-23 | 1999-05-19 | Zeneca Ltd | Chemical compounds |
| GB9924092D0 (en) | 1999-10-13 | 1999-12-15 | Zeneca Ltd | Pyrimidine derivatives |
| EP1343505A1 (en) | 2000-12-11 | 2003-09-17 | Tularik Inc. | Cxcr3 antagonists |
| GB0124931D0 (en) * | 2001-10-17 | 2001-12-05 | Glaxo Group Ltd | Chemical compounds |
| TW200306839A (en) | 2002-02-06 | 2003-12-01 | Novartis Ag | Quinazolinone derivatives and their use as CB agonists |
| SI1864975T1 (sl) * | 2002-02-12 | 2011-01-31 | Glaxosmithkline Llc | Nikotinamidni derivati, uporabni kot inhibitorji p38 |
| WO2005005153A1 (en) * | 2003-07-10 | 2005-01-20 | Koninklijke Philips Electronics N.V. | Method and device for accurately positioning a pattern on a substrate |
| EP2251333A1 (en) * | 2003-07-25 | 2010-11-17 | Novartis AG | Biphenyl derivatives as P-38 kinase inhibitors |
| GB0329572D0 (en) | 2003-12-20 | 2004-01-28 | Astrazeneca Ab | Amide derivatives |
| ATE500227T1 (de) * | 2004-12-24 | 2011-03-15 | Astrazeneca Ab | Amidderivate |
| GB0504019D0 (en) * | 2005-02-26 | 2005-04-06 | Astrazeneca Ab | Amide derivatives |
| GB0516570D0 (en) | 2005-08-12 | 2005-09-21 | Astrazeneca Ab | Amide derivatives |
-
2003
- 2003-10-24 GB GBGB0324790.5A patent/GB0324790D0/en not_active Ceased
-
2004
- 2004-10-21 TW TW093132022A patent/TWI343378B/zh not_active IP Right Cessation
- 2004-10-22 EP EP04768990A patent/EP1682520B1/en not_active Expired - Lifetime
- 2004-10-22 UA UAA200604496A patent/UA83867C2/ru unknown
- 2004-10-22 AT AT04768990T patent/ATE499347T1/de not_active IP Right Cessation
- 2004-10-22 CN CN2012103938753A patent/CN103012376A/zh active Pending
- 2004-10-22 MX MXPA06004465A patent/MXPA06004465A/es active IP Right Grant
- 2004-10-22 AR ARP040103862A patent/AR046308A1/es not_active Application Discontinuation
- 2004-10-22 ES ES04768990T patent/ES2359409T3/es not_active Expired - Lifetime
- 2004-10-22 MY MYPI20044370A patent/MY140729A/en unknown
- 2004-10-22 WO PCT/GB2004/004474 patent/WO2005042502A1/en not_active Ceased
- 2004-10-22 UY UY28578A patent/UY28578A1/es not_active Application Discontinuation
- 2004-10-22 AU AU2004285749A patent/AU2004285749B2/en not_active Ceased
- 2004-10-22 NZ NZ547095A patent/NZ547095A/en not_active IP Right Cessation
- 2004-10-22 CN CNA2004800390365A patent/CN1898216A/zh active Pending
- 2004-10-22 RU RU2006117326/04A patent/RU2375352C2/ru not_active IP Right Cessation
- 2004-10-22 DE DE602004031543T patent/DE602004031543D1/de not_active Expired - Lifetime
- 2004-10-22 BR BRPI0415746-0A patent/BRPI0415746A/pt not_active IP Right Cessation
- 2004-10-22 CA CA2543351A patent/CA2543351C/en not_active Expired - Fee Related
- 2004-10-22 SG SG200807338-9A patent/SG147409A1/en unknown
- 2004-10-22 US US10/576,808 patent/US7750154B2/en not_active Expired - Fee Related
- 2004-10-22 KR KR1020067010003A patent/KR101127697B1/ko not_active Expired - Fee Related
- 2004-10-22 JP JP2006536171A patent/JP4987478B2/ja not_active Expired - Fee Related
- 2004-10-23 SA SA04250351A patent/SA04250351B1/ar unknown
-
2006
- 2006-04-20 IL IL175065A patent/IL175065A/en not_active IP Right Cessation
- 2006-04-21 ZA ZA200603226A patent/ZA200603226B/en unknown
- 2006-05-11 IS IS8450A patent/IS8450A/is unknown
- 2006-05-24 NO NO20062370A patent/NO20062370L/no not_active Application Discontinuation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007509118A5 (enExample) | ||
| RU2006117326A (ru) | Амидные производные | |
| US7442704B2 (en) | Amide derivatives | |
| KR101985050B1 (ko) | 피라진카르복사미드 화합물 | |
| US20030186966A1 (en) | Amide derivatives | |
| SK285520B6 (sk) | Amidové deriváty, spôsob ich prípravy, farmaceutický prostriedok s ich obsahom a ich použitie na prípravu liečiva na liečbu stavov sprostredkovaných cytokínmi | |
| CA2382605A1 (en) | Pyrimidine derivatives | |
| SK1762001A3 (en) | Amide derivatives useful as inhibitors of the production of cytokines | |
| WO2005082865A1 (ja) | 縮合二環性ピリミジン誘導体 | |
| JP2008501675A (ja) | Ｅｒｂｂ受容体型チロシンキナーゼとしてのキナゾリン誘導体 | |
| US20090036474A1 (en) | Quinazoline derivatives for use against cancer | |
| HK1041885B (en) | Amide derivatives | |
| ZA200106857B (en) | Amide derivatives. | |
| MXPA01009308A (en) | Amide derivatives | |
| CZ20011093A3 (cs) | Amidové deriváty, které jsou užitečné jako inhibitory produkce cytokinů, způsob jejich přípravy a farmaceutický prostředek, který je obsahuje |